Literature DB >> 34027045

EPHA2, a promising therapeutic target for hepatocellular carcinoma.

Hao Wang1,2, Wei Qiu1,2.   

Abstract

Identifying critical drivers of oncogenesis and tumor progression is essential for developing effective hepatocellular carcinoma (HCC) therapeutics. Our recent findings has demonstrated that targeting Ephrin Receptor A2 (EPHA2) suppresses HCC initiation and progression by dual inhibition of the Protein Kinase B (AKT) and Signal Transducer and Activator of Transcription 3 (STAT3) signaling.
© 2021 Taylor & Francis Group, LLC.

Entities:  

Keywords:  AKT; EPHA2; HCC; JAK1; STAT3

Year:  2021        PMID： 34027045      PMCID： PMC8128187          DOI： 10.1080/23723556.2021.1910009

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  Mechanisms of ephrin-Eph signalling in development, physiology and disease.

Authors:  Artur Kania; Rüdiger Klein
Journal:  Nat Rev Mol Cell Biol       Date:  2016-01-21       Impact factor: 94.444

Review 2.  AKT as a Therapeutic Target for Cancer.

Authors:  Mengqiu Song; Ann M Bode; Zigang Dong; Mee-Hyun Lee
Journal:  Cancer Res       Date:  2019-02-26       Impact factor: 12.701

Review 3.  Hepatocellular Carcinoma.

Authors:  Augusto Villanueva
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

Review 4.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions.

Authors:  Hua Yu; Heehyoung Lee; Andreas Herrmann; Ralf Buettner; Richard Jove
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

5.  Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.

Authors:  Katherine R Amato; Shan Wang; Andrew K Hastings; Victoria M Youngblood; Pranav R Santapuram; Haiying Chen; Justin M Cates; Daniel C Colvin; Fei Ye; Dana M Brantley-Sieders; Rebecca S Cook; Li Tan; Nathanael S Gray; Jin Chen
Journal:  J Clin Invest       Date:  2014-04-08       Impact factor: 14.808

Review 6.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

7.  EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.

Authors:  Hui Miao; Da-Qiang Li; Amitava Mukherjee; Hong Guo; Aaron Petty; Jennifer Cutter; James P Basilion; John Sedor; Jiong Wu; David Danielpour; Andrew E Sloan; Mark L Cohen; Bingcheng Wang
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

8.  Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.

Authors:  Yongmun Choi; Farisa Syeda; John R Walker; Patrick J Finerty; Dominic Cuerrier; Amy Wojciechowski; Qingsong Liu; Sirano Dhe-Paganon; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2009-05-13       Impact factor: 2.823

9.  Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.

Authors:  Hao Wang; Wei Hou; Aldeb Perera; Carlee Bettler; Jordan R Beach; Xianzhong Ding; Jun Li; Mitchell F Denning; Asha Dhanarajan; Scott J Cotler; Cara Joyce; Jun Yin; Fowsiyo Ahmed; Lewis R Roberts; Wei Qiu
Journal:  Cell Rep       Date:  2021-02-23       Impact factor: 9.423

10.  Gene Expression Profiling of Muscle Stem Cells Identifies Novel Regulators of Postnatal Myogenesis.

Authors:  Sonia Alonso-Martin; Anne Rochat; Despoina Mademtzoglou; Jessica Morais; Aurélien de Reyniès; Frédéric Auradé; Ted Hung-Tse Chang; Peter S Zammit; Frédéric Relaix
Journal:  Front Cell Dev Biol       Date:  2016-06-21
  10 in total
  1 in total

1.  CLEC14A was up-regulated in hepatocellular carcinoma and may function as a potential diagnostic biomarker.

Authors:  Lang Yan; Xiang Li; Yunfeng Yuan
Journal:  Clinics (Sao Paulo)       Date:  2022-05-13       Impact factor: 2.898
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.